Nicole Stingle

TL;DR: Preliminary evidence that toceranib exhibits CB in dogs with certain solid tumours is provided, although future prospective studies are necessary to define its true activity.

TL;DR: The addition of toceranib to metronomic piroxicam/cyclophosphamide therapy following amputation and carboplatin chemotherapy did not improve median DFI, OS or the 1-year survival rate in dogs with OSA.

TL;DR: Evidence of significant activity (71% objective response) and enhanced myelosuppression suggest additive or synergistic activity and a prospective randomized evaluation comparing this combination with standard single-agent treatments would seem prudent to interrogate this potential.

TL;DR: Citrated recalcified (nonactivated) TEG demonstrated changes consistent with hypocoagulability in horses with colitis that had preidentified coagulation abnormalities, indicating this technique has high interindividual variability and low intra-assay variability.

TL;DR: Results are comparable to those reported for carboplatin monotherapy indicating that the addition of gemcitabine tocarboplatin in dogs with appendicular OSA does not appear to improve outcome.